Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

This article is part of the supplement: AIDS Vaccine 2012

Open Access Open Badges Poster presentation

A prime-boost immunization with rBCG expressing HIV-1 Gag, RT and gp120 and SAAVI MVA-C elicits immune responses in blood and MALT of rhesus macaques

GK Chege*, R Chapman, EG Shephard and A Williamson

  • * Corresponding author: GK Chege

Author Affiliations

University of Cape Town, Cape Town, South Africa

For all author emails, please log on.

Retrovirology 2012, 9(Suppl 2):P40  doi:10.1186/1742-4690-9-S2-P40

The electronic version of this article is the complete one and can be found online at:

Published:13 September 2012

© 2012 Chege et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


BCG pantothenate auxtroph (ΔpanCD) is safer to use as a live vaccine vector than wild-type BCG. We constructed 3 recombinant BCGΔpanCD candidate vaccines expressing HIV-1 subtype C Gag, RT and Env (gp120). The current study investigated immune responses in rhesus macaques following a prime with a mixture of these rBCG vaccines and a boost with SAAVI MVA-C (MVA).


Chinese rhesus macaques (n=8) were primed twice with a mixture of rBCG, 12 weeks apart. A control group (n=4) was mock-primed with a control BCG. Both groups were boosted with MVA. Two weeks after the MVA vaccination, two macaques from the rBCG-primed group were euthanased and jejunum, spleen and inguinal, mesenteric, iliac and bronchial lymph nodes were harvested for isolation of mononuclear cells. HIV-1-specific IFN-gamma ELISPOT responses were measured in the blood and these tissues using pools of overlapping HIV-1 peptides.


Vaccination with rBCG elicited modest HIV-specific responses in the blood in 5 of 8 animals, 4 of which responded after the first rBCG vaccination. These responses were to either Env or to both Env and Gag proteins and the cumulative responses ranged from 50 to 172 sfu/106 PBMC. After boosting with MVA, HIV-specific responses were detected in 6 of the 8 animals (mean: 932±1100 sfu/106 PBMC). These responses were directed to Gag, RT, and Env proteins but not Nef or Tat. No responses were detected in the control animals before or after MVA vaccination. At necropsy, HIV-specific responses were detected in the peripheral blood, spleen, inguinal, iliac and bronchial lymph nodes of 1 of 2 animals. The cumulative responses ranged from 112 to 714 sfu/106 cell input.


These data demonstrate that our rBCGΔpanCD candidate vaccines, when given in a prime-boost combination with SAAVI MVA-C, induce vaccine-specific immune responses in both the peripheral blood and MALT.